title: Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
abstract: For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this therapy; however, their indicated treatment duration of 1 to 4 months was still not long enough to satisfy all medical needs. For this reason some manufacturers developed new injectable formulations that provide testosterone suppression for 6 months. This review article assesses key publications in order to compare these long-acting, commercially available, LA depot formulations and their clinical performance. The literature search identified 14 publications; by excluding reviews, duplications, and non-English articles, only three original papers describing clinical trial remained for review: two focused on microsphere-based LA formulations with either a 30 mg or 45 mg dose and one focused on a gel-based leuprorelin acetate with a 45 mg dose. All products were tested in individual clinical trials and have demonstrated their efficacy and safety.
authors: Urological Department, Prostate Center, Offenbach, Germany. info@uro-privat.de
authors: Ulf W
authors: UW
authors: Tunn
authors: Damian
authors: D
authors: Gruca
authors: Peter
authors: P
authors: Bacher
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000737:chemistry* / Q000494:pharmacology*; D002626:Chemistry, Pharmaceutical; D006801:Humans; D016729:Leuprolide / Q000737:chemistry* / Q000494:pharmacology*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide
keywords: GnRH agonist; androgen deprivation therapy; leuprolide acetate; leuprorelin acetate; prostate cancer
references: J Urol. 2002 Sep;168(3):1199-203
references: 12187267
references: J Clin Endocrinol Metab. 2012 Feb;97(2):360-5
references: 22162475
references: BJU Int. 2012 Jun;109 Suppl 6:22-32
references: 22672122
references: Prog Urol. 1998 Dec;8(6):1087-96
references: 9894276
references: Int J Clin Pract. 2002 Jun;56(5):389-96
references: 12137449
references: Cancer Res. 2008 Aug 1;68(15):6407-15
references: 18676866
references: Int J Urol. 2012 Jul;19(7):614-25
references: 22435512
references: Urol Int. 1998;60 Suppl 1:9-16; discussion 16-7
references: 9563139
references: J Urol. 2006 Feb;175(2):533-6
references: 16406989
references: Urol Int. 1998;60 Suppl 2:18-24; discussion 35
references: 9607554
references: J Clin Psychiatry. 2010 Dec;71(12):1696-8
references: 21190641
references: BMC Urol. 2011 Jul 29;11:15
references: 21801354
references: Adv Drug Deliv Rev. 1997 Oct 13;28(1):121-138
references: 10837568
references: Urol Int. 1996;56 Suppl 1:23-30
references: 8776814
references: Prog Urol. 2011 Nov;21(12):866-74
references: 22035913
references: Fertil Steril. 1971 Nov;22(11):703-21
references: 4941683
references: Ann Intern Med. 2000 Apr 4;132(7):566-77
references: 10744594
references: Expert Opin Pharmacother. 2004 Feb;5(2):447-57
references: 14996640
references: Expert Rev Anticancer Ther. 2005 Aug;5(4):605-11
references: 16111462
references: Clin Interv Aging. 2009;4:259-67
references: 19554097
references: Prostate Cancer Prostatic Dis. 2012 Mar;15(1):93-9
references: 22025196
references: Arch Esp Urol. 2010 May;63(4):275-81
references: 20508303
references: Clin Ther. 2002 Nov;24(11):1902-14
references: 12501882
references: CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
references: 4625049
references: BJU Int. 2007 Jul;100 Suppl 1:6-11
references: 17593202
references: JAMA. 1998 Sep 16;280(11):969-74
references: 9749478
references: Clin Ther. 1996 Jul-Aug;18(4):647-57
references: 8879893
references: J Urol. 2002 Sep;168(3):1001-4
references: 12187208
references: Cancer Manag Res. 2011;3:201-9
references: 21847353
references: J Urol. 1990 Jan;143(1):68-71
references: 2104638
references: Eur Urol. 2011 Apr;59(4):572-83
references: 21315502
references: Prostate Cancer Prostatic Dis. 2009;12(1):83-7
references: 19030021
references: J Androl. 2004 May-Jun;25(3):305-13
references: 15064303
references: AAPS PharmSciTech. 2000 Feb 28;1(1):E1
references: 14727850